1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,450 | 7,000 | 04.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.12.25 | Akari begins GMP manufacturing of lead ADC program with WuXi XDC | 3 | Investing.com | ||
| 23.12.25 | Akari startet GMP-Produktion für führendes ADC-Programm mit WuXi XDC | 1 | Investing.com Deutsch | ||
| 19.12.25 | JPM Sees CN Healthcare Sector Pullback as Entry Opportunity, Raises TPs for INNOVENT BIO/WUXI XDC | 2 | AASTOCKS | ||
| 12.12.25 | WUXI XDC (02268): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 12, 2025 | 1 | HKEx | ||
| 01.12.25 | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| 25.11.25 | WUXI XDC (02268): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON FRIDAY, DECEMBER 12, 2025 | 1 | HKEx | ||
| 25.11.25 | WUXI XDC (02268): NOTICE OF EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| WUXI XDC Aktie jetzt für 0€ handeln | |||||
| 25.11.25 | WUXI XDC (02268): CONTINUING CONNECTED TRANSACTIONS (1) REVISION OF ANNUAL CAP FOR THE EXISTING ANTIBODIES MASTER SERVICES AGREEMENT (2) RENEWAL OF THE ... | 2 | HKEx | ||
| 25.11.25 | WUXI XDC (02268): CLOSURE OF REGISTER OF MEMBERS | - | HKEx | ||
| 25.11.25 | WUXI XDC (02268): SUPPLEMENTAL ANNOUNCEMENT CONTINUING CONNECTED TRANSACTIONS (1) REVISION OF ANNUAL CAPS FOR RELEVANT CCT AGREEMENTS; (2) RENEWAL OF ... | - | HKEx | ||
| 21.11.25 | UBS stuft WuXi XDC mit "Buy" ein - starkes Wachstum im Biokonjugat-Markt erwartet | - | Investing.com Deutsch | ||
| 23.10.25 | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| 23.10.25 | WUXI XDC (02268): COMPLETION OF CONNECTED TRANSACTION INVOLVING SUBSCRIPTION OF NEW SHARES UNDER SPECIFIC MANDATE | 3 | HKEx | ||
| 09.10.25 | WUXI XDC (02268): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON OCTOBER 9, 2025 | - | HKEx | ||
| 26.09.25 | WUXI XDC (02268): INTERIM REPORT 2025 | 2 | HKEx | ||
| 23.09.25 | WUXI XDC (02268): CONTINUING CONNECTED TRANSACTIONS (1) REVISION OF ANNUAL CAPS FOR RELEVANT CCT AGREEMENTS; (2) RENEWAL OF EXISTING CCT AGREEMENTS; AND ... | 3 | HKEx | ||
| 22.09.25 | WUXI XDC (02268): FORM OF PROXY FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON THURSDAY, OCTOBER 9, 2025 | 1 | HKEx | ||
| 22.09.25 | WUXI XDC (02268): NOTICE OF EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| 22.09.25 | WUXI XDC (02268): CONNECTED TRANSACTION IN RELATION TO SUBSCRIPTION OF NEW SHARES UNDER SPECIFIC MANDATE AND NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 19.09.25 | WUXI XDC (02268): CLOSURE OF REGISTER OF MEMBERS | 3 | HKEx |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PROTAGONIST THERAPEUTICS | 87,18 | -0,18 % | Protagonist Therapeutics: Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice | NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qualifications... ► Artikel lesen | |
| COGENT BIOSCIENCES | 34,740 | -2,20 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 286,40 | -2,83 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor | The Breakthrough Therapy Designation was granted based on the positive topline results from the Essential3 Phase 3 program in essential tremor Praxis remains on track to submit ulixacaltamide NDA... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,09 | -0,06 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 72,76 | -6,49 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | WATERTOWN, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,000 | -0,14 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,880 | -1,97 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,500 | -5,42 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 75,78 | +0,41 % | BTIG bestätigt Kaufempfehlung für Apogee Therapeutics angesichts positiver Aussichten | ||
| NUVALENT | 100,84 | +0,25 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| QIAGEN | 38,425 | -1,11 % | QIAGEN N.V.: QIAGEN gibt Details zum Abschluss des synthetischen Aktienrückkaufs über bis zu rund $500 Mio. bekannt | Kapitalrückzahlung durch synthetischen Aktienrückkauf kombiniert schnelle, unmittelbare Kapitalrückzahlung an Aktionärinnen und Aktionäre mit einer Aktienzusammenlegung zur Steigerung des Gewinns... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,200 | +2,69 % | JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline | ||
| IMMUNOME | 20,820 | -3,07 % | Immunome: Guggenheim bestätigt Kaufempfehlung nach 400-Millionen-Dollar-Finanzierung | ||
| ARS PHARMACEUTICALS | 11,490 | -1,37 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,140 | -2,09 % | Do You Think Beam Therapeutics (BEAM) is an Undervalued Stock? |
Das Unternehmen WUXI XDC CAYMAN INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 6,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu WUXI XDC CAYMAN INC finden Sie auf Wallstreet Online.